Annovis Bio Inc. (NYSE: ANVS), a late-stage clinical drug platform company developing therapies for neurodegenerative diseases, announced it will present new findings on its lead candidate buntanetap at the 2025 Annual Meeting of the Parkinson Study Group, taking place Dec. 4–6 in San Diego. The presentation will expand on recent Phase 3 Parkinson’s biomarker results, which indicate that patients with amyloid co-pathology experience more severe cognitive decline that is reversed by buntanetap. The drug also reduces tau biomarkers linked to disease progression.
In addition to these findings, Annovis will debut a cross-study comparison of all completed trials, offering the most comprehensive view to date of cognitive outcomes across indications. This analysis underscores that patients with amyloid pathology achieve the greatest cognitive benefit, supporting the company’s strategic path forward. The presentation will provide a deeper understanding of buntanetap’s mechanism and its potential to address neurodegeneration in both Alzheimer’s and Parkinson’s diseases.
Annovis Bio is headquartered in Malvern, Pennsylvania, and is dedicated to addressing neurodegeneration in diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD). The company is committed to developing innovative therapies that improve patient outcomes and quality of life. For more information, visit www.annovisbio.com and follow the company on LinkedIn, YouTube, and X.
For the full press release, visit https://ibn.fm/xiBPL. The latest news and updates relating to ANVS are available in the company’s newsroom at https://ibn.fm/ANVS.
This announcement is significant because it provides new evidence that buntanetap can reverse cognitive decline in a subset of Parkinson’s patients with amyloid co-pathology, a condition associated with more rapid disease progression. The cross-study comparison further strengthens the case for buntanetap’s efficacy across neurodegenerative diseases, potentially broadening its therapeutic application. Investors and researchers will be keen to see the detailed data presented at the meeting, which could influence the drug’s development path and future clinical trials.
